Immunoglobulin G antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response

Journal of Virology

Volumn 80, Issue 17, 2006, Pages 8530-8540

  Iankov, Ianko D ^a   Pandey, Manoj ^a   Harvey, Mary ^a   Griesmann, Guy E ^a   Federspiel, Mark J ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HEMAGGLUTININ; IMMUNOGLOBULIN G ANTIBODY; MEASLES VACCINE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MACROPHAGE; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CELL LINE; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MACROPHAGES; MEASLES; MEASLES VACCINE; MEASLES VIRUS; MICE; MICE, TRANSGENIC; MONOCYTES; U937 CELLS; VIRAL FUSION PROTEINS;

MEASLES VIRUS; MORBILLIVIRUS; MURINAE; MUS MUSCULUS;

EID: 33748659233     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00593-06     Document Type: Article

References (50)

1. Aderem, A., and D. M. Underhill. 1999. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17:593-623.
2. Anderson, B. D., T. Nakamura, S. J. Russell, and K. W. Peng. 2004. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 64:4919-4926.
3. Cardosa, M. J., J. S. Porterfield, and S. Gordon. 1983. Complement receptor mediates enhanced flavivirus replication in macrophages. J. Exp. Med. 158:258-263.
4. Christiansen, D., P. Devaux, B. Reveil, A. Evlashev, B. Horvat, J. Lamy, C. Rabourdin-Combe, J. H. Cohen, and D. Gerlier. 2000. Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo. J. Virol. 74:4672-4678.
5. Devaux, P., D. Christiansen, S. Plumet, and D. Gerlier. 2004. Cell surface activation of the alternative complement pathway by the fusion protein of measles virus. J. Gen. Virol. 85:1665-1673.
6. Duprex, W. P., S. McQuaid, B. Roscic-Mrkic, R. Cattaneo, C. McCallister, and B. K. Rima. 2000. In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J. Virol. 74:7972-7979.
7. Esolen, L. M., B. J. Ward, T. R. Moench, and D. E. Griffin. 1993. Infection of monocytes during measles. J. Infect. Dis. 168:47-52.
8. Fulginiti, V. A., J. J. Eller, A. W. Downie, and C. H. Kempe. 1967. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202:1075-1080.
9. Gerber, J. S., and D. M. Mosser. 2001. Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J. Immunol. 166:6861-6868.
10. Giraudon, P., and T. F. Wild. 1985. Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity. Virology 144:46-58.
11. Grazia Cappiello, M., F. S. Sutterwala, G. Trinchieri, D. M. Mosser, and X. Ma. 2001. Suppression of Il-12 transcription in macrophages following Fc gamma receptor ligation. J. Immunol. 166:4498-4506.
12. Griffin, D. 2001. Measles virus, p. 1401-1441. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
13. Grote, D., S. J. Russell, T. I. Cornu, R. Cattaneo, R. Vile, G. A. Poland, and A. K. Fielding. 2001. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97:3746-3754.
14. Haralambieva, I. H., I. D. Iankov, D. P. Petrov, I. V. Mladenov, and I. G. Mitov. 2002. Monoclonal antibody of IgG isotype against a cross-reactive lipopolysaccharide epitope of Chlamydia and Salmonella Re chemotype enhances infectivity in L-929 fibroblast cells. FEMS Immunol. Med. Microbiol. 33:71-76.
15. Heinzerling, L., V. Kunzi, P. A. Oberholzer, T. Kundig, H. Naim, and R. Dummer. 2005. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106:2287-2294.
16. Iinuma, M., K. Maeno, H. Nagura, and T. Matsumoto. 1979. Enhancement of fusion from within by antiviral antibody in cells infected with Newcastle disease virus. Microbiol. Immunol. 23:1037-1041.
17. Marie, J. C., J. Kehren, M. C. Trescol-Biemont, A. Evlashev, H. Valentin, T. Walzer, R. Tedone, B. Loveland, J. F. Nicolas, C. Rabourdin-Combe, and B. Horvat. 2001. Mechanism of measles virus-induced suppression of inflammatory immune responses. Immunity 14:69-79.
18. Marth, T., and B. L. Kelsall. 1997. Regulation of interleukin-12 by complement receptor 3 signaling. J. Exp. Med. 185:1987-1995.
19. Meissner, H. C., P. M. Strebel, and W. A. Orenstein. 2004. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 114:1065-1069.
20. Morrison, T. G. 2003. Structure and function of a paramyxovirus fusion protein. Biochim. Biophys. Acta 1614:73-84.
21. Moss, W. J., J. J. Ryon, M. Monze, and D. E. Griffin. 2002. Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children. J. Infect. Dis. 186:879-887.
22. Moss, W. J., M. O. Ota, and D. E. Griffin. 2004. Measles: immune suppression and immune responses. Int. J. Biochem. Cell Biol. 36:1380-1385.
23. Mrkic, B., J. Pavlovic, T. Rulicke, P. Volpe, C. J. Buchholz, D. Hourcade, J. P. Atkinson, A. Aguzzi, and R. Cattaneo. 1998. Measles virus spread and pathogenesis in genetically modified mice. J. Virol. 72:7420-7427.
24. Nakamura, T., K. W. Peng, M. Harvey, S. Greiner, I. A. Lorimer, C. D. James, and S. J. Russell. 2005. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23:209-214.
25. Naniche, D., G. Varior-Krishnan, F. Cervoni, T. F. Wild, B. Rossi, C. Rabourdin-Combe, and D. Gerlier. 1993. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67:6025-6032.
26. Norrby, E., G. Enders-Ruckle, and V. Meulen. 1975. Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J. Infect. Dis. 132:262-269.
27. Otten, M., R. Kezaala, A. Fall, B. Masresha, R. Martin, L. Cairns, R. Eggers, R. Biellik, M. Grabowsky, P. Strebel, J. M. Okwo-Bele, and D. Nshimirimana. 2005. Public-health impact of accelerated measles control in the WHO African Region 2000-03. Lancet 366:832-839.
28. Peng, K. W., C. J. TenEyck, E. Galanis, K. R. Kalli, L. C. Hartmann, and S. J. Russell. 2002. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62:4656-4662.
29. Peng, K. W., G. J. Ahmann, L. Pham, P. R. Greipp, R. Cattaneo, and S. J. Russell. 2001. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98:2002-2007.
30. Peng, K. W., M. Frenzke, R. Myers, D. Soeffker, M. Harvey, S. Greiner, E. Galanis, R. Cattaneo, M. J. Federspiel, and S. J. Russell. 2003. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum. Gene Ther. 14:1565-1577.
31. Peng, K. W., S. Facteau, T. Wegman, D. O'Kane, and S. J. Russell. 2002. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. 8:527-531.
32. Peterson, E. M., X. Cheng, S. Pal, and L. M. de la Maza. 1993. Effects of antibody isotype and host cell type on in vitro neutralization of Chlamydia trachomatis. Infect. Immun. 61:498-503.
33. Peterson, E. M., X. Cheng, V. L. Motin, and L. M. de la Maza. 1997. Effect of immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse model of intravaginal infection. Infect. Immun. 65:2693-2699.
34. Phuong, L. K., C. Allen, K. W. Peng, C. Giannini, S. Greiner, C. J. TenEyck, P. K. Mishra, S. I. Macura, S. J. Russell, and E. C. Galanis. 2003. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63:2462-2469.
35. Polack, F. P., P. G. Auwaerter, S. H. Lee, H. C. Nousari, A. Valsamakis, K. M. Leiferman, A. Diwan, R. J. Adams, and D. E. Griffin. 1999. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5:629-634.
36. Polack, F. P., S. J. Hoffman, G. Crujeiras, and D. E. Griffin. 2003. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med. 9:1209-1213.
37. Polack, F. P., S. J. Hoffman, W. J. Moss, and D. E. Griffin. 2002. Altered synthesis of interleukin-12 and type 1 and type 2 cytokines in rhesus macaques during measles and atypical measles. J. Infect. Dis. 185:13-19.
38. Rall, G. F. 2003. Measles virus 1998-2002: progress and controversy. Annu. Rev. Microbiol. 57:343-367.
39. Reisinger, E. C., W. Vogetseder, D. Berzow, D. Kofler, G. Bitterlich, H. A. Lehr, H. Wachter, and M. P. Dierich. 1990. Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937. AIDS 4:961-965.
40. Roscic-Mrkic, B., R. A. Schwendener, B. Odermatt, A. Zuniga, J. Pavlovic, M. A. Billeter, and R. Cattaneo. 2001. Roles of macrophages in measles virus infection of genetically modified mice. J. Virol. 75:3343-3351.
41. Schneider, U., V. von Messling, P. Devaux, and R. Cattaneo. 2002. Efficiency of measles virus entry and dissemination through different receptors. J. Virol. 76:7460-7467.
42. Slifka, M. K., D. Homann, A. Tishon, R. Pagarigan, and M. B. Oldstone. 2003. Measles virus infection results in suppression of both innate and adaptive immune responses to secondary bacterial infection. J. Clin. Investig. 111:805-810.
43. Suhrbier, A., and M. La Linn. 2003. Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol. 24:165-168.
44. Takada, A., H. Feldmann, T. G. Ksiazek, and Y. Kawaoka. 2003. Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77:7539-7544.
45. Takeda, A., C. U. Tuazon, and F. A. Ennis. 1988. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242:580-583.
46. Tatsuo, H., N. Ono, K. Tanaka, and Y. Yanagi. 2000. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406:893-897.
47. Trinchieri, G., S. Pflanz, and R. A. Kastelein. 2003. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19:641-644.
48. Underhill, D. M., and A. Ozinsky. 2002. Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol. 20:825-852.
49. Ward, B. J., S. Aouchiche, N. Martel, F. M. Bertley, N. Bautista-Lopez, B. Serhir, and S. Ratnam. 1999. Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test. Diagn. Microbiol. Infect. Dis. 33:147-152.
50. Woof, J. M., and D. R. Burton. 2004. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 4:89-99.